Skip to main content

Published locations for Ligelizumab outperformed omalizumab for refractory chronic spontaneous urticaria

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ligelizumab outperformed omalizumab for refractory chronic spontaneous urticaria

User login

  • Reset your password
  • /content/ligelizumab-outperformed-omalizumab-refractory-chronic-spontaneous-urticaria
  • /edermatologynews/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic
  • /familypracticenews/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic
  • /internalmedicinenews/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic
  • /internalmedicine/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic
  • /dermatology/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic
  • /familymedicine/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic